GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration has approved its asthma drug Nucala as an add-on maintenance treatment for adults with chronic obstructive pulmonary ...

Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

Shares of GSK PLC GSK rose 1.02% to £14.30 Wednesday, on what proved to be an all-around positive trading session for the ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...